Patient Leaflet Updated 01-Sep-2021 | Amgen Ltd
Kyprolis
Kyprolis 10 mg powder for solution for infusion
Kyprolis 30 mg powder for solution for infusion
Kyprolis 60 mg powder for solution for infusion
carfilzomib
1. What Kyprolis is and what it is used for
2. What you need to know before you use Kyprolis
3. How to use Kyprolis
4. Possible side effects
5. How to store Kyprolis
6. Contents of the pack and other information
Kyprolis is a medicine that contains the active substance carfilzomib.
Carfilzomib works by blocking the proteasome. The proteasome is a system within the cells that breaks down proteins when they are damaged or no longer needed. By preventing the breakdown of proteins in cancer cells, which are more likely to contain more abnormal proteins, Kyprolis causes the death of cancer cells.
Kyprolis is used to treat adult patients with multiple myeloma who have had at least one previous treatment for this disease. Multiple myeloma is a cancer of plasma cells (a type of white blood cell).
Kyprolis will be given to you together with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or only with dexamethasone. Daratumumab, lenalidomide and dexamethasone are other medicines used to treat multiple myeloma.
Your doctor will examine you and review your full medical history. You will be monitored closely during treatment. Before starting Kyprolis, and during treatment, you will undergo blood testing. This is to check that you have enough blood cells and your liver and kidneys are working properly. Your doctor or nurse will check if you are getting enough fluids.
You must read the package leaflet of all medicines that you take in combination with Kyprolis so that you understand the information related to those medicines.
Do not use Kyprolis if you are allergic to carfilzomib or any of the other ingredients of this medicine (listed in section 6).
Talk to your doctor or nurse before using Kyprolis if you have any of the conditions listed below.
You may need extra tests to check that your heart, kidneys and liver are working properly.
Conditions you need to look out for
You must look out for certain symptoms while you are taking Kyprolis to reduce the risk of any problems. Kyprolis can make some conditions worse or cause serious side effects, which may be fatal, such as heart problems, lung problems, kidney problems, tumour lysis syndrome (a life-threatening condition that occurs when cancer cells break and release their content to the bloodstream), reactions to the Kyprolis infusion, unusual bruising or bleeding, (including internal bleeding), blood clots in your veins, liver problems, certain blood conditions, or a neurological condition known as PRES. See ‘Conditions you need to look out for’ in section 4.
Tell your doctor if you have ever had or might now have a hepatitis B infection. This is because this medicine could cause hepatitis B virus to become active again. Your doctor will check you for signs of this infection before, during and for some time after treatment with this medicine. Tell your doctor right away if you get worsening tiredness, or yellowing of your skin or white part of your eyes.
At any time during or after your treatment, tell your doctor or nurse immediately if you: experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion. These may all be symptoms of a serious and potentially fatal brain condition known as Progressive Multifocal Leukoencephalopathy (PML). If you had these symptoms prior to treatment with carfilzomib, tell your doctor about any change in these symptoms.
Tell your doctor if you are taking, have recently taken or might take any other medicines. This includes any medicines obtained without a prescription, such as vitamins or herbal remedies.
Tell your doctor or nurse if you are taking medicines used to prevent pregnancy such as oral contraceptives or other hormonal contraceptives, as these may not be suitable for use with Kyprolis.
For women taking Kyprolis
Do not take Kyprolis if you are pregnant, think you may be pregnant or are planning to have a baby. Treatment with Kyprolis has not been evaluated in pregnant women. While taking Kyprolis, and for 30 days after stopping treatment you should use a suitable method of contraception to ensure you do not become pregnant. You should talk to your doctor or nurse about suitable methods of contraception.
If you become pregnant while taking Kyprolis, notify your doctor or nurse immediately.
Do not take Kyprolis if you are breast-feeding. It is not known if Kyprolis passes into breast milk in humans.
Lenalidomide is expected to be harmful to the unborn child. As Kyprolis is given in combination with lenalidomide, you must follow the Pregnancy Prevention Programme (see package leaflet for lenalidomide for information on pregnancy prevention and discuss with your doctor, pharmacist or nurse).
For men taking Kyprolis
While taking Kyprolis and for 90 days after stopping treatment, you should use a condom even if your partner is pregnant.
If your partner becomes pregnant whilst you are taking Kyprolis or within 90 days after stopping treatment, notify your doctor or nurse immediately.
While you are being treated with Kyprolis you may experience fatigue, dizziness, fainting, and/or a drop in blood pressure. This may impair your ability to drive or operate machines. Do not drive a car or operate machines if you have these symptoms.
This medicine contains 37 mg sodium per 10 mg vial. This is equivalent to 1.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
This medicine contains 109 mg sodium per 30 mg vial. This is equivalent to 5.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
This medicine contains 216 mg sodium per 60 mg vial. This is equivalent to 11% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
This medicine contains 500 mg cyclodextrin (betadex sulfobutyl ether sodium) per 10 mg vial. This is equivalent to 88 mg/kg for a 70 kg adult.
This medicine contains 1,500 mg cyclodextrin (betadex sulfobutyl ether sodium) per 30 mg vial. This is equivalent to 88 mg/kg for a 70 kg adult.
This medicine contains 3,000 mg cyclodextrin (betadex sulfobutyl ether sodium) per 60 mg vial. This is equivalent to 88 mg/kg for a 70 kg adult.
Kyprolis will be given to you by a doctor or nurse. The dose will be calculated based on your height and weight (body surface area). Your doctor or nurse will determine the dose of Kyprolis that you receive.
Kyprolis will be given as an infusion into a vein. The infusion may last up to 30 minutes. Kyprolis is given 2 days in a row each week, for 3 weeks, followed by one week without treatment.
Each 28-day period is one treatment cycle. This means that Kyprolis will be given to you on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The doses on day 8 and 9 of each cycle will not be given from cycle 13 onwards if you are treated with Kyprolis in combination with lenalidomide and dexamethasone.
Most patients will receive treatment for as long as their disease improves or remains stable. However, Kyprolis treatment may also be stopped if you experience side effects that cannot be managed.
Together with Kyprolis you will also be given either lenalidomide and dexamethasone, daratumumab and dexamethasone, or only dexamethasone. You may also be given other medicines.
As this medicine is being given by a doctor or nurse, it is unlikely that you will be given too much. However, if you are given too much Kyprolis your doctor will monitor you for side effects.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects could be serious. Tell your doctor straight away if you get notice any of the following symptoms:
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
Kyprolis will be stored in the pharmacy.
Keep this medicine out of the sight and reach of children.
Do not use Kyprolis after the expiry date printed on the vial and the carton. The expiry date refers to the last day of that month.
Store refrigerated (2°C - 8°C).
Do not freeze.
Store in the original carton in order to protect from light.
The reconstituted product should be a clear, colourless to slightly yellow solution and should not be administered if any discolouration or particulate matter is observed.
Kyprolis is for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.
Kyprolis is supplied in a glass vial as a white to off-white powder for solution for infusion, which is reconstituted (dissolved) before use. The reconstituted solution is a clear, colourless or slightly yellow solution.
Each pack contains 1 vial.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
This leaflet was last revised in August 2021
216 Cambridge Science Park, Milton Road, Cambridge, CB4 0WA, UK
+44 (0)1223 426 314
+44 (0)1223 420 305
+44 (0)1223 436 441
+44 (0)1223 426 314